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Medical School, Boston, MA 02115, USAHereditary hearing loss often results from mutation of genes
expressed by cochlear hair cells. Gene addition using AAV vec-
tors has shown some efﬁcacy in mouse models, but clinical
application requires two additional advances. First, new AAV
capsids must mediate efﬁcient transgene expression in both in-
ner and outer hair cells of the cochlea. Second, to have the best
chance of clinical translation, these new vectors must also
transduce hair cells in non-human primates. Here, we show
that an AAV9 capsid variant, PHP.B, produces efﬁcient trans-
gene expression of a GFP reporter in both inner and outer hair
cells of neonatal mice. We show also that AAV9-PHP.B medi-
ates almost complete transduction of inner and outer HCs in a
non-human primate. In a mouse model of Usher syndrome
type 3A deafness (geneCLRN1), we use AAV9-PHP.B encoding
Clrn1 to partially rescue hearing. Thus, we have identiﬁed a vec-
tor with promise for clinical treatment of hereditary hearing
disorders, and we demonstrate, for the ﬁrst time, viral trans-
duction of the inner ear of a primate with an AAV vector.Received 13 November 2018; accepted 14 November 2018;
https://doi.org/10.1016/j.omtm.2018.11.003.
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Hearing loss occurs in approximately 1/1,000 births, with roughly half
having a genetic cause. The disease burden is substantial and lifelong.
Many of the deafness genes identiﬁed affect hair cells (HCs), the sen-
sory cells of the inner ear, so a promising strategy to treat hereditary
deafness is gene delivery to HCs with viral vectors. Adeno-associated
virus (AAV) serotype 1 vector has been used for viral transduction of
HCs; however, it only transduces inner HCs (IHCs) and not the
equally important outer HCs (OHCs).1,2 Studies using AAV8 have
shown variable results transducing OHCs via round window mem-
brane (RWM) injection.3,4
Recently, our group and others demonstrated efﬁcient gene delivery
to IHCs and OHCs in neonatal mice, using new AAV-based sys-Molecular Therapy: Methods
This is an open access article under the CC BY-Ntems.5–7 Both represent signiﬁcant advances over conventional
AAV1. However, signiﬁcant challenges remain for clinical translation
of AAV-based gene therapy for deafness. First, gene transfer to the co-
chlea has been performed almost exclusively in neonatal mice, with
no reports in non-human primates (NHPs), so the translational po-
tential of various AAVs for cochlear gene therapy in humans is un-
known. Second, in many human hereditary deafnesses, the HCs are
thought to degenerate during development, so postnatal gene therapy
interventions might have no target.8 Thus, many studies showing
rescue of hearing in neonatal mice in models of human deafness do
not necessarily apply to humans.
To address these issues, we ﬁrst sought a gene delivery vector for
effective gene therapy to all cochlear HCs, in several relevant species.
We used GFP expression to assess the efﬁcacy of a recently described
AAV9 capsid variant, AAV9-PHP.B, which was originally selected for
transduction of central neurons after systemic delivery in mice.9
AAV9-PHP.B mediated efﬁcient transgene expression in the IHCs
and OHCs of neonatal mice and rats and produced transgene expres-
sion in many cochlear cell types in juvenile macaque, including HCs.
As a model, we selected the recessive deafness and blindness disorder
Usher syndrome type 3A (Usher 3A; caused by mutations in CLRN1).
In Usher 3A, the hearing loss is not profound at birth but is& Clinical Development Vol. 13 June 2019 ª 2018 The Author(s). 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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www.moleculartherapy.orgprogressive, providing a reasonable window for AAV-mediated gene
therapy intervention.We used AAV9-PHP.B to deliver a normal copy
of the Clrn1 coding sequence to cochleas in a mouse model of Usher
3A and found signiﬁcant rescue of hearing. Together, these data sup-
port a feasible path toward clinical development of a gene therapy for
hereditary hearing loss.
RESULTS
AAV9-PHP.B Efficiently Transduces Hair Cells in Neonatal Mice
First, we tested the transduction efﬁciency of AAV9-PHP.B capsid
using a single-stranded (ss) AAV transgene expression cassette,
with a GFP reporter driven by the chicken beta actin (CBA) pro-
moter. The scalae tympani of the cochleas of neonatal C57BL/6
mice were injected via the RWM at postnatal day 1 (P1) with
5  1010 vector genomes (VGs) of AAV9-PHP.B-CBA-GFP. Five
days later, mice were sacriﬁced, and cochlear explants were cultured
for one additional day before ﬁxation and GFP expression analysis.
We observed robust transduction in the spiral ganglion region, sen-
sory epithelium, and lateral wall of the cochlea (Figures 1A and 1B;
Figure S1). Higher magniﬁcation images of the sensory epithelium
revealed efﬁcient GFP expression in both IHCs and OHCs (Figures
1C and 1D) but not in the supporting cells surrounding the HCs.
Transduction efﬁciency was 60%–80% for IHCs and 30%–40% for
OHCs, depending on the location (Figure 1E; Figure S2). For
OHCs, there was a signiﬁcant gradient of transduction from apex
to base, with more efﬁcient transduction in the apex (linear regres-
sion, R2 = 0.83, p = 0.029), but for IHCs, there was no statistically
signiﬁcant gradient.
In one animal (out of ﬁve), we observed vector transduction of a few
cells in the uninjected contralateral ear (Figure S3). It is possible that
some vector diffused through cerebrospinal ﬂuid to the other ear in a
neonatal animal.
We also injected adult (4-week-old C57BL/6) mice with 2 1010 VGs
of AAV9-PHP.B-CBA-GFP through the posterior semicircular canal.
Although almost all IHCs from apex to base were transduced, no
OHC transduction was observed (Figures S4A and S4B), suggesting
that, in mice, AAV9-PHP.B can transduce OHCs only in neonates
(at least for the tested delivery routes). We observed robust transduc-
tion of the vestibular system (Figure S4C).
Hordeaux et al. recently found that the enhanced transduction of CNS
neurons in C57BL/6mice by systemically administered AAV9-PHP.B
did not translate to the BALB/cJ mouse strain,10 so we asked whether
AAV9-PHP.B efﬁcacy in the neonatal C57BL/6 mouse cochlea wouldFigure 1. Transduction Efficiency in C57BL/6J Mice of AAV9-PHP.B-CBA-GFP
(A) Low-magnification images of the cochlea showing the highest transduction level. W
5 1010 vector genomes (VGs), and the cochlea was explanted at P5 and cultured for an
overlaid with phalloidin staining. SGN, spiral ganglion neurons; SE, sensory epithelium
regions of the cochlea with the highest transduction. (D) High-magnification images of t
IHCs (left panel) and OHCs (right). Bars indicate mean ± SEM. To determine the specifie
cochleas (for details, see Figure S2). Not all the cochleas had a preserved basal region
Molecextend to neonatal CD1 mouse cochlea. Injection of AAV9-PHP.B-
GFP into P1 CD1 mice resulted in robust GFP expression in both
IHCs and OHCs in the cochlea (Figures 2A and 2B). We observed
60%–80% transduction of IHCs and 40%–70% transduction of
OHCs (Figure 2C). There was signiﬁcantly higher transduction efﬁ-
ciency in CD1 animals compared to that in C57BL/6 animals (Fig-
ure 2D) (Mann-Whitney test, p < 0.04 for IHCs, and p < 0.004 for
OHCs; data are from all regions analyzed).
Finally, we asked whether efﬁcacy translates to another rodent spe-
cies, Sprague-Dawley rats. We injected two P1 neonatal pups via
the RWM at a dose of 1.2  1010 VGs. As in neonatal mice, we
observed GFP-positive cells in the regions of spiral ganglion, sensory
epithelium, and lateral wall. The transduction efﬁciency was higher in
one of the injected rats (Figures S5A and S5B); higher magniﬁcation
of the sensory epithelium in that animal revealed robust IHC and
OHC transduction (Figure S5A).
Taken together, these results conﬁrm that the AAV9-PHP.B capsid is
an efﬁcient vector to target neonatal sensory HCs in two strains of
mice as well as in rats.
Clrn1 Expression in the Murine Inner Ear
To test AAV9-PHP.B in an animal model of hereditary deafness, we
ﬁrst selected a deafness gene for which postnatal treatment is
feasible in human. In Usher 3A (caused by mutations in CLRN1),
the hearing loss is not profound at birth but is progressive,
providing a reasonable window for AAV-mediated gene therapy.
We ﬁrst investigated normal Clrn1 expression in the developing in-
ner ear. The Shared Harvard Inner-Ear Laboratory Database
(SHIELD11) revealed highly enriched expression of Clrn1 in
cochlear and vestibular HCs relative to non-HCs (Figure S6A).
Alternative splice forms of Clrn1 have been identiﬁed, so we sepa-
rately dissected organs of Corti and spiral ganglion regions from
embryonic day (E)17 up to P7 in CD1 mice and performed RT-
PCR with primers in exon 1 and exon 4. RT-PCR analysis revealed
that isoform 2 of Clrn1 (containing exons 1, 3, and 4) was the pre-
dominant mRNA species expressed at all ages (Figure S7); however,
isoform 3 (containing exons 1 and 4) was also expressed. Based on
the predicted tertiary structure of clarin 1 (Figure S6B) and the fact
that the CLRN1 sequence is highly conserved between species (Fig-
ure S6C), we anticipate that isoform 3 would not be functional, as it
would lack a conserved transmembrane domain. Isoform 2 was
found to be predominant in the retina as well.12 For therapeutic
application, therefore, we cloned the mouse codon-optimized
cDNA of isoform 2 of Clrn1 into the AAV expression cassette.after Neonatal RWM Injection
T, wild-type. (B) The median transduction (n = 15). Animals were injected at P1 with
other day (P5+1). The left panel shows GFP staining only; the right panel shows GFP
; SV, stria vascularis; SL, spiral limbus. (C) High-magnification images of different
he cochlea with median transduction. (E) Quantification of transduction efficiency in
d regions, we measured the distance from the apex and used the same value for all
, so there are fewer data points for the base.
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Figure 2. Transduction Efficiency in CD1 Mice of AAV9-PHP.B-CBA-GFP after Neonatal RWM Injection
(A) Low-magnification image of a representative injection in CD1 mouse. Animals (n = 5) were injected at P1 with 5  1010 VGs, and cochleas were explanted at P5 and
cultured for another day (P5+1). Left panel shows GFP staining only; right panel shows GFP overlaid with phalloidin staining. (B) High-magnification image of the sensory
epithelium of mid-apex region from the same cochlea as in (A). (C) Quantification of transduction efficiency in IHCs and OHCs. Error bars indicate mean ± SEM.
(D) Transduction efficiency in CD1 compared to C57BL/6J mice (unpaired t test, p < 0.001 for IHCs, and p < 0.009 for OHCs; data are from all regions analyzed).
Molecular Therapy: Methods & Clinical DevelopmentLack of Clrn1 Leads to Hair Cell Dysfunction
To establish a baseline for rescue, we evaluated the phenotype of
Clrn1/. First, we performed a simple dye loading assay in cochlear
explants from heterozygous Clrn1+/ or knockout Crln1/ mice. At
P5+1, loading of the styryl dye FM1-43 was signiﬁcantly decreased in
both IHCs and OHCs in knockout mice compared to heterozygotes,
indicating impaired mechanotransduction (Figure S8; unpaired t test
for all regions combined, p < 0.0001 for both IHCs and OHCs) and
conﬁrming the results of Geng et al.13 Analysis of Clrn1/ hair
bundle morphology revealed loss of orientation and disorganization
of hair bundles at P5+1, beginning as early as P0+1 (Figure S9).
AAV9-PHP.B-Mediated Clrn1 Expression in Hair Cells Results in
Restoration of Hearing in a Mouse Model of Usher 3A
For AAV-mediated Clrn1 expression in HCs, we packaged Clrn1 iso-
form 2 under the control of the CBA promoter into AAV9-PHP.B (ss
genome) with an N-terminal hemagglutinin (HA) tag to allow anti-
body detection (Figure S10). We observed expression of Clrn1
mRNA by RT-PCR and of CLRN1 protein by immunostaining, after
transfection of the plasmid into 293T cells (Figure S11). Next, we in-
jected 7.4  1010 VGs of AAV9-PHP.B-CBA-HA-Clrn1 into
Clrn1/ animals at P1. As expected from previous reports,13 we4 Molecular Therapy: Methods & Clinical Development Vol. 13 June 201found robust immunostaining with an anti-HA antibody of Clrn1
in the hair bundles of IHCs and OHCs. There was staining also in
the kinocilium and cuticular plate region (Figures 3A and 3B). Cell
bodies showed diffuse immunostaining (Figure 3B). Importantly,
transduction efﬁciency of vector encoding HA-CLRN1 was similar
to that seen with vector encoding GFP, with more efﬁcient transduc-
tion in the apex compared to that in the base (Figure 3C).
Finally, to test whether we could rescue hearing inClrn1/mice with
gene addition therapy, we injected P1 cochleas through the RWM
with 1.8  1011 VGs of untagged AAV9-PHP.B-Clrn1 (n = 17). Un-
injected mice (n = 10) were used as controls. Four weeks post-injec-
tion, an auditory brainstem response (ABR) recording was performed
at different frequencies (Figure 3D). Measurement of ABRs in unin-
jected control Clrn1/ mice (n = 10) indicated that they are almost
completely deaf by P25, with limited residual hearing in a few animals
at 11.3–16 kHz. AAV-injected Clrn1/ mice showed robust hearing
rescue at lower frequencies (4–8 kHz); however, there was little or no
rescue at the highest frequencies. The absence of rescue at higher fre-
quencies could be related to the relatively low AAV9-PHP.B-medi-
ated CLRN1 expression in the base (Figure 3C). The best hearing
restoration was a 50-dB reduction in threshold in two animals at 49
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Figure 3. AAV-Mediated Clrn1 Delivery Restores Protein Expression in IHCs and OHCs and Rescues Hearing in Clrn1 KO Animals
(A) Anti-HA immunostaining of injected C57BL/6J mice. Animals were injected at P1 through the RWMwith 7.4 1010 VGs of AAV9-PHP.B-CBA-HA-Clrn1. Cochleas were
explanted at P5 and were cultured for another day (P5+1). Hair bundles were counterstained with phalloidin. (B) Higher magnification images of IHCs and OHCs at different
focal planes. Strong fluorescence labeling was observed in the hair bundle region, cuticular plate, and kinocilium. In the cell body, diffuse cytoplasmic staining was detected.
(legend continued on next page)
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Molecular Therapy: Methods & Clinical Developmentand 5.6 kHz. Compared to non-injected animals, hearing restoration
was signiﬁcant at 4, 5.6, 8, and 11 kHz (Wilcoxon test, p < 0.05 for all
indicated frequencies) (Figure S12A). When we compared injected
(left) versus non-injected (right) ears, we also observed signiﬁcantly
lower thresholds in injected ears at 4, 5.6, and 8 kHz (Wilcoxon
test, p < 0.05 for all indicated animals) (Figure S12B).
We also ascertained whether injection of AAV9-PHP.B-Clrn1 would
adversely affect the ABR thresholds of normal-hearing mice, a mea-
sure of potential vector-related toxicity. P1 wild-type C57BL/6 mice
were injected with 4.12  1010 VGs of AAV9-PHP.B-Clrn1, and
4 weeks later, an ABR assay was performed. We observed no distor-
tion of ABR thresholds in injected mice compared to those in un-
treated mice, suggesting that the surgery and vector expression was
well tolerated (Figure 3E).
AAV9-PHP.B Transduces Retinal Cells in Mice
Because Usher 3A patients show late-onset blindness due to retinal
degeneration, we tested the ability of AAV9-PHP.B-GFP to transduce
retinal cells after subretinal injections (2.1  109 VGs) in adult
C57BL/6 mice (n = 6 retinas injected). With fundus imaging, we
observed widespread retinal transduction 8 days post-injection (Fig-
ure 4A) in 4 of 6 injected eyes (in 2 eyes, the injections failed). Micro-
scopy revealed robust (70%–80%) photoreceptor transduction at
the injection site in AAV9-PHP.B-GFP-injected eyes (Figure 4B),
along with some GFP-positive cells in the inner nuclear layer (INL)
and ganglion cell layer (GCL). Results from the other three eyes
with successful injection are shown in Figure S13. These results sug-
gest that the AAV-PHP.B capsid can be used to target both inner ear
HCs and retinal photoreceptors.
AAV9-PHP.B Transduces Cells in NHP Inner Ear after RWM
Injection
As a step toward clinical translation to humans, we asked whether
IHCs and OHCs can be transduced by AAV9-PHP.B in NHPs.
A male juvenile cynomolgus monkey (animal #1002) was injected
in one ear via the RWM with a dose of 3  1011 VGs of AAV9-
PHP.B-GFP in a volume of 10 mL, using a trans-mastoid approach
similar to that reported by Dai et al.14 The contralateral (left) ear
was used as a control. Seven weeks later, the animal was sacriﬁced,
the temporal bone was extracted and decalciﬁed over 3 months,
and the cochlea was sectioned for histological analysis (Figure 5A).
H&E examination of the injected and noninjected cochleas indicated
little change associated with the surgery and vector injection. We
observed small bone fragments in the middle ear, with minimal
inﬂammation and slight ﬁbrous tissue, which is consistent with tem-
poral bone fragments generated during the surgical procedure. Exam-
ination of sections of the cochlea in the injected ear revealed mild(C) Proportion of inner and outer hair cells with HA-positive bundles. Blue traces indica
brainstem response (ABR) of mice injected with AAV9-PHP.B-CBA-Clrn1 (tagless, no H
vector-injected (right panel; n = 17) and non-injected (left panel; n = 10) animals. In e
comparison (n = 2; mean ± SD). (E) ABR testing of AAV9-PHP.B-mediated expression
6 Molecular Therapy: Methods & Clinical Development Vol. 13 June 201hemorrhage, which is expected with this surgical procedure. We de-
tected some inﬂammatory cells in the noninjected cochlea. The
HCs, stria vascularis, and spiral ganglion neurons had normal
morphology (Figures S14 and S15).
We then used anti-GFP antibodies to assess GFP expression in both
uninjected and injected ears. While no speciﬁc staining was observed
in the uninjected ear (Figure 5B, bottom, and 5C, top left), we
observed robust GFP immunoreactivity throughout the cochlea in
the injected ear (Figure 5B, top). GFP appeared in the organ of Corti,
spiral ligament, spiral limbus, and stria vascularis, from the base to the
apex. Higher magniﬁcation revealed GFP expression by HCs in the
organ of Corti (Figure 5C). Quantitation of GFP immunoreactive
HCs in cochlear turns in serial sections revealed 92% transduction
of IHCs and 92% of OHCs. Widespread transduction in the lateral
wall was observed as well (Figure 5D). Additionally, GFP expression
was detected with lower intensity in the spiral ganglion neurons
(Figure 5E).
We subsequently injected both cochleas of a female juvenile macaque
(animal #3501) with 1 1011 VGs of AAV9-PHP.B-GFP in a volume
of 10 mL. ABR assays were performed before surgery and 8 weeks
post-surgery. ABR waveforms were quite similar in the left injected
ear pre- and post-surgery, although the right ear showed some eleva-
tion in hearing thresholds compared to pre-treatment waveforms
(Figure S16). The animal was killed on the day after ABR, and co-
chleas were processed for histology and immunostaining). H&E ex-
amination of the injected cochleas indicated little change associated
with the surgery and vector injection (Figures S17 and S18), similar
to animal #1002. In contrast to animal #1002, we observed limited
transduction in both injected cochleas in animal #3501. The very
fewGFP-positive cells weremostly Claudius cells in the organ of Corti
and a few cells in the lateral wall (Figure S19). No obvious HC trans-
duction was observed in either cochlea in this animal, perhaps
because of the lower dose used or perhaps because of a failure of vec-
tor injection.
DISCUSSION
Our results demonstrate that the AAV capsid, AAV9-PHP.B, can
mediate efﬁcient transduction of both IHCs and OHCs in the co-
chleas of neonatal mice, neonatal rats, and a juvenile NHP. Deter-
mining the translation potential of AAV capsids is important, as there
have been reports of species differences in tropism and transduction.
For example, while AAV8 vectors have shown high tropism for hepa-
tocytes in mouse models, they appear to have a preference for murine
hepatocytes over human hepatocytes in humanized liver models.15
Similarly, the AAV9-PHP.B capsid was selected for transduction of
the CNS, from a randomized heptamer peptide library inserted in
the AAV9 capsid, after intravenous injection of the library in mice.9te individual animals (n = 6); dashed red traces indicate mean ± SEM. (D) Auditory
A tag, 1.8  1011 VGs were injected). An ABR assay was performed at 4 weeks for
ach panel, the ABR from 4-week-old wild-type C57BL/6J animals is indicated for
of Clarin1 on hearing in wild-type C57BL/6J mice (n = 7; mean ± SD).
9
Figure 4. Transduction of Mouse Retina with AAV9-PHP.B-CBA-GFP
Adult (4.5-month-old) C57/BL6 mice were injected subretinally with 2.1  109 VG
(1 mL). (A) Many retinal cells were transduced 8 days post-injection. (B) Numerous
photoreceptors were GFP positive as well as a few cells in the ganglion cell layer
(GCL; small arrowheads) and the inner nuclear layer (INL; large arrowhead). GCL,
ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; IS, inner
segment; OS, outer segment.
www.moleculartherapy.orgAAV9-PHP.B is, arguably, the most efﬁcient AAV vector at transduc-
tion of mouse neurons and astrocytes after systemic injection to date,
with great enhancement over AAV9. However, while the enhance-Molecment was conﬁrmed in the mouse strain in which the library was
selected, this enhancement was not observed in NHPs.10,16
We ﬁrst tested PHP.B in the inner ear with the goal of identifying
AAV vectors that could mediate efﬁcient transduction as an ss
genome, in order to achieve maximum packaging capacity (4.7
kb). We have previously observed that self-complementary (sc)
AAV1 vectors are more efﬁcient than ss AAV1 vectors (data not
shown), although sc encoding reduces transgene cassette packaging
capacity to 2.3 kb. As HCs are not closely related to neurons or as-
trocytes, we were surprised to see the striking efﬁciency of the trans-
duction of IHCs andOHCs after local injection of AAV9-PHP.B. This
capsid displays a 7-mer peptide, TLAVPFK, between amino acids 588
and 589 (numbering fromVP1 protein).9 However the mechanism by
which AAV9-PHP.B mediates efﬁcient HC transduction is not
yet clear.
A number of other AAV variants have been tested for efﬁcacy in the
expression of exogenous genes in HCs of neonatal mice. AAV1 was
found by both Akil et al.1 and Askew et al.2 to transduce most
IHCs, but few OHCs, in neonatal mouse cochlea. For proteins that
are primarily expressed only in IHCs, such as the VGLUT3 trans-
porter,1 AAV1 was adequate for rescue of deafness in a mouse model.
However most deafness genes in HCs encode proteins needed in both
IHCs and OHCs, so efﬁcient targeting of OHCs is essential. AAV2
and AAV8 were used by Geng et al.,3 with only slightly better results:
both transduced IHCs and some OHCs, although the transduction ef-
ﬁciency was not quantiﬁed. Dulon et al.17 also used AAV8 and trans-
duced 90% of IHCs but only 10% of OHCs. Better results were
found with a synthetic AAV, Anc80L65: in the very best cases, nearly
100% of IHCs and OHCs were transduced. With the delivery of
1.4  109 VGs of Anc80, 30%–60% of IHCs and 10%–60% of
OHCs were transduced, whereas there was essentially no transduc-
tion by AAV1, AAV2, and AAV8 at the same dose.6 For most of these
vectors in most studies, efﬁcacy was higher at the low-frequency apex
of the cochlea than at the high-frequency base.
AAV9-PHP.B compares favorably to these vectors. At 5  1010 VGs
with RWM injection of C57BL/6 mice at P0, it transduced 50%–70%
of IHCs and up to 100% in the best cases. OHCs were also transduced,
at 30%–40% on average and up to 75%. AAV9-PHP.B transduced
CD1 mice at even higher rates: 80% of IHCs and 50% of OHCs.
In adult mice, the transduction proﬁle of HCs differed from that of
neonates. Because injection through the RWM in adult mice can
damage hearing, delivery can be performed by injection into the pos-
terior semi-circular canal. Vector apparently diffuses easily to the
cochlea in mice, because cochlear HCs are readily transduced. With
canal injections of 1  109 VGs of Anc80L65, Suzuki et al.18 found
that nearly all IHCs were transduced and that between 90% (apex)
and 20% (base) of the OHCs were transduced. Similarly, a compre-
hensive comparison of eight AAV variants (AAV1, AAV2, AAV6.2,
AAV8, AAV9, rh.39, rh.43, and Anc80L65; 1–2  1010 VGs) with
canal injections in adult mice19 found that most showed <25%ular Therapy: Methods & Clinical Development Vol. 13 June 2019 7
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Figure 5. Transduction Profile of AAV9-PHP.B-CBA-GFP in the Cynomolgus Monkey (Animal #1002)
Vector (10 mL; 3 1011 VGs) was injected through the RWM of a 2.6-year-old, 4-kgMacaca fascicularismonkey. (A) Experimental protocol. (B) Low-magnification images of
the injected ear (top) and non-injected (bottom) ear. Anti-GFP staining was detected with a horseradish-peroxidase-conjugated secondary antibody and developed using
(legend continued on next page)
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www.moleculartherapy.orgtransduction of IHCs and little, if any, transduction in OHCs, with the
exception of Anc80L65 (80%–100% IHCs and 2%–50% OHCs). In
adult mice, canal injection of AAV9-PHP.B produced good transduc-
tion of IHCs but little efﬁcacy in OHCs. Use of AAV9-PHP.B in mice
for gene delivery to both IHCs and OHCs will likely be best for
neonatal treatment.
Usher syndromes are characterized by the loss of both hearing and
vision, so gene addition to retinal photoreceptors as well as HCs
will be needed for comprehensive therapy. We observed that, with
subretinal injection, AAV9-PHP.B transduces a large fraction of pho-
toreceptors in adult mice (Figure 4). Gianelli et al.20 found that the
same vector transduces a substantial fraction of rods and cones
with intravitreal injection as well.
Before clinical trials in humans, it will be necessary to show good ef-
ﬁcacy in the cochlear HCs of a closely related primate. We found that
AAV9-PHP.B transduced IHCs and OHCs in the cochlea of a juvenile
male cynomolgus macaque (animal #1002) following RWM injection
of 3 1011 VGs. Over 90% of both IHCs and OHCs were transduced
in all sections from apex to base. In contrast, a second cynomolgus
macaque (animal #3501, a juvenile female) showed extremely limited
transduction, with no obvious transduction of HCs. One explanation
of the discrepancy in transduction efﬁciency between the two animals
could be dose related, as a 3-fold higher dose was utilized in animal
#1002 that displayed efﬁcient HC transduction. Other possible expla-
nations are gender differences, genetic variability between animals,
and the success of the RWM injections. Another unknown factor is
whether pre-existing immunity to AAV (i.e., anti-AAV antibodies
due to prior exposure to wild-type AAV) in perilymph can affect
the transduction of cochlea. The two NHPs utilized in this study
were not prescreened for anti-AAV antibodies, and future studies
will need to be performed to evaluate whether transduction is
inversely correlated with antibody titer, as has been observed with
systemically and, sometimes, locally (intravitreal injection21) admin-
istered AAV. While these results demonstrate that it is feasible to
transduce the inner ear of NHPs, further, extensive studies with larger
group sizes are required to understand variables that may affect the
transduction of various inner ear cell types.
The trans-mastoid surgical procedure in cynomolgous monkeys can
be challenging, with the potential risk, as in humans, of damage to
the facial nerve. The challenge of the surgery and visualization of
proper insertion depth of the needle through the RWM is another
possible explanation for the lower transduction in the second NHP
(animal #3501). While the narrow ear canal of the macaque necessi-
tates this alternate surgical approach, in humans, the RWM is easier
to access using a trans-canal route. Despite the invasive trans-mastoid
approach necessary for RWM injection in NHPs, the surgery was welldiaminobenzidine (brown areas). Slides were counterstained with hematoxylin. (C) Highe
lacks GFP-specific immunoreactivity. The numbers in the cochlear turns in (B) corresp
arrows. (D) Transduction of the lateral wall at high (top) and low (bottom) magnification. (E
the injected ear (top) but not the non-injected ear (bottom).
Molectolerated. Histological examination of animals post-injection revealed
normal anatomical integrity, indicating minimal pathology related to
the vector/surgery.
The high efﬁcacy of AAV9-PHP.B in HCs of neonatal mice allowed
partial rescue of hearing in a mouse knockout model of Usher 3A.
Adult mice lacking a functional Clrn1 gene are profoundly deaf.13,22
With neonatal injection of AAV9-PHP.B encoding CLRN1, we
achieved an increase of up to 50 dB in sensitivity, primarily in low-fre-
quency regions. In Usher 3A mouse models that preserve expression
of Clrn1 for a week or more after birth, better mimicking the human
disease, other vectors encoding CLRN1 show efﬁcient rescue of hear-
ing,3,17 so we anticipate that AAV9-PHP.B will show even better
rescue in these models. It is also important to note that Geng et al.3
tested a vector that included the 50 and 30 UTRs of murine Clarin
and that this led to a greater rescue of hearing than the AAV-Clrn1
vector that did not contain the UTR. Thus, future work with
AAV9-PHP.B-Clrn1 should contain the UTRs.
In conclusion, AAV9-PHP.B efﬁciently transduces the IHCs and
OHCs of neonatal mouse and in one out of two injected NHPs. These
data warrant further preclinical studies in NHPs to evaluate this vec-
tor as a potential candidate for cochlear gene therapy.
MATERIALS AND METHODS
AAV Vector Constructs
We used an AAV transgene plasmid, ﬂanked by AAV2 inverted ter-
minal repeats (ITRs), encoding GFP under the hybrid cytomegalo-
virus (CMV) immediate-early/CBA promoter, and with a woodchuck
hepatitis virus posttranscriptional regulatory element (WPRE). This
vector (AAV-CBA-GFP-W) encodes a ss genome. The helper
plasmid pAdDF623 was obtained from the Massachusetts General
Hospital Vector Core. The pGG-PHP.B plasmid encoding the rep
genes of AAV2 and the AAV9 variant, AAV9-PHP.B,9 was provided
by Dr. Miguel Sena-Esteves (University of Massachusetts Medical
School), who synthesized the capsid sequence based on the published
sequence. We constructed an AAV ITR-containing plasmid encoding
murine Clrn1. The open reading frame of isoform 2 of Clrn2 was syn-
thesized by GenScript (Piscataway, NJ, USA) and cloned into a ss
AAV-expression (AAV-CBA-W) plasmid into the multiple cloning
site to generate AAV-CBA-Clrn1-W. We also had HA-tagged Clrn1
constructs synthesized (GenScript) and cloned them similarly into
AAV-CBA-W.
To test whether the constructed plasmids expressed CLRN1,
HEK293T cells were transiently transfected (calcium phosphate
method) with each of the following plasmids in separate wells:
AAV-CBA-Clrn1 (no tag), AAV-CBA-HA-Clrn1, and AAV-CBA-
Clrn1-HA. AAV-HA-Lhfpl5 was a previously characterized plasmidr magnification images of the organ of Corti from base to apex. The non-injected ear
ond to panels 1–4. IHCs are indicated with arrowheads; OHCs are indicated with
) Transduction of spiral ganglion neurons.We observed dim but consistent staining in
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positive control for HA staining. Forty-eight hours post-transfection,
a subset of wells was harvested for RNA harvest, while another set was
harvested for immunoﬂuorescence staining of the HA tag.
Vector Production and Purification
For each production, we plated ten 15-cm tissue culture dishes with
1.5  107 293T cells per dish. The next day, cells were transfected
using the calcium phosphate method, with the adenovirus helper
plasmid (pAdDF6, 26 mg), rep/cap plasmid (pGG-PHP.B for
AAV9-PHP.B, 12 mg), and ITR-ﬂanked transgene cassette plasmid
(10 mg) to induce production of AAV. The day after transfection,
medium was changed to DMEM containing 2% fetal bovine serum
(FBS). AAV was puriﬁed from the cell lysate using iodixanol
density-gradient ultracentrifugation. Buffer exchange to PBS was
conducted using Zeba spin columns (7K MWCO; Thermo Fisher
Scientiﬁc) and further concentration was performed using Amicon
Ultra 100-kDa MWCO ultraﬁltration centrifugal devices (Milli-
pore). Vectors were stored at 80C until use. We quantiﬁed
AAV genomic copies in AAV preparations using TaqMan qPCR
with bovine growth hormone (BGH) poly(A) sequence-speciﬁc
primers and probe.24 During the course of this study, several inde-
pendent preparations of AAV9-PHP.B vector were made, with each
having slightly different titers. As we used the maximum injectable
volume in each model (1.2 mL for neonatal mice and 10 mL for
macaques), this resulted in differences in the dose between some ex-
periments. All doses used are indicated in the ﬁgure legends and/or
Results section.
Mouse Housing and Breeding
All experiments were performed in compliance with ethical regula-
tions approved by the Animal Care Committee of Harvard Medical
School (HMS). Wild-type pregnant C57BL/6 females were ordered
from Charles River Laboratories, and pups were used for AAV-
CBA-GFP transduction experiments. Clrn1 knockout (KO) animals,
in which the ﬁrst coding exon was deleted,21 were a generous gift
from Dr. Kumar Alagramam (Case Western Reserve University).
Genotyping was done as previously described.22 They were housed
and bred at the HMS animal facility.
Mouse RWM Injection in Neonatal Mice
P0–P1 CD1 and C57BL/6 pups were anesthetized by hypothermia
and then kept on an ice pack during the procedure. As previously
described,5 a small incision was made underneath the external ear.
The incision was enlarged, and soft tissues were pushed apart using
an eyelid retractor to expose the bulla. Then the round window niche
was localized visually. Covering connective tissue was removed to
expose the round window. For GFP expression experiments, we in-
jected 1.0–1.2 mL of AAV9-PHP.B-CBA-GFP vector solution at rate
of 60 nL/min. For rescue experiments, we injected 1.0–1.2 mL of the
AAV9-PHP.B-CBA-Clrn1 vector into the ear, which encodes
CLRN1 without the HA tag. For immunostaining to detect CLRN1
encoded by the AAV, we used the vector encoding an N-terminal
HA-tagged CLRN1. We closed surgical incisions with 2–3 sutures us-10 Molecular Therapy: Methods & Clinical Development Vol. 13 June 20ing a 7-0 Vycril surgical suture. After injection, we waited 5 days
before sacriﬁce to assess vector transduction.
Adult Mouse Injection
4-week-old mice were anesthetized with ketamine (100 mg/kg) and
xylazine (20 mg/kg) through an intraperitoneal injection. Both eyes
were protected by an application of eye gel (GenTeal lubricant eye
gel). The fur behind the left ear was shaved with a sterile razor, and
the surgical area was cleansed two times with antiseptic solution, iso-
lated with sterile drapes, and swabbed along the proposed incision
with 10% povidone-iodine. We used a surgical procedure similar to
that described by Suzuki et al.18 A small (10- to 15-mm) postauricular
skin incision was made. After exposing the facial nerve and the ster-
nocleidomastoid muscle by blunt dissection, the tissue covering the
temporal was separated and retracted using the magnetic retractor
set. A small hole was made with a microprobe in the exposed bony
wall of the posterior canal. We waited 2–3 min for leakage of peri-
lymph to stop, and then inserted the tip of a MicroFil 35G needle
into the hole. The aperture between the MicroFil needle and the
hole was sealed with tissue fragments and cyanoacrylate glue (3 M
Vetbond Tissue Adhesive) and visually assessed for lack of ﬂuid
leakage. 1 mL viral suspension at 155 nL/min was injected using the
Nanoliter 2000 Injector (World Precision Instruments). After the in-
jection was completed, the plastic needle remained in the canal for
5 min and then was cut off proximally to the canal. The hole was ﬁlled
in with tissue and sealed with glue. The wound was closed with 5-0
Vicryl-coated sutures and swabbed with 10% povidone-iodine. The
mouse was placed on a heating pad until full recovery. Animals
received an intraperitoneal injection of meloxicam (0.01 mL/g body
weight) after surgery and once more within the ﬁrst 24 hr. Injected
mice were checked daily for 5 days following surgery.
Mouse Cochlear Immunostaining and Imaging
For FM1-43 loading, organ of Corti epithelium was acutely dissected
from P5 mice in L-15 cell culture medium and cultured for an addi-
tional day in DMEM supplemented with 5% FBS and ampicillin
(10 mg/L). Following tectorial membrane removal and medium aspi-
ration, FM1-43 solution (2 mM in L-15) was applied to the tissue for
30–60 s and then quickly aspirated. The explant was then rinsed once
with L-15, and the excessive dye was quenched by a 0.2 mM solution
of 4-sulphonate calixarene, sodium salt (SCAS, Biotium), in L-15. The
organ of Corti was then observed on an upright Olympus FV1000
confocal microscope, equipped with a 60 1.1-NA water-dipping
objective lens.
For immunostaining, cochleas were ﬁxed with 4% formaldehyde in
PBS for 20 min. Fixed cochleas were washed 3 times with PBS to re-
move ﬁxative and were blocked with 5% normal goat serum and per-
meabilized with 0.3% Triton X-100 in PBS for 1 hr at 22C. Primary
antibodies were diluted in 5% normal goat serum (NGS)/0.1% Triton
X-100/PBS and incubated overnight at 4C. To label HCs, we used
rabbit polyclonal anti-myosin VIIa antibody (Proteus Biosciences;
1:500 dilution) with a goat anti-rabbit immunoglobulin G (IgG) sec-
ondary antibody conjugated to Alexa Fluor 647 in a 1:1,000 dilution19
www.moleculartherapy.orgfor 1 hr (Life Technologies). To stain the hair bundle actin, we used
phalloidin conjugated to Alexa Fluor 544 (Life Technologies)
(1:50). To detect the HA tag, we used a rabbit anti-HA antibody
(C29F4; Cell Signaling Technology). GFP was detected via its intrinsic
ﬂuorescence (i.e., no immunostaining for GFP). Tissues were
mounted on a Colorfrost glass slide (Thermo Fisher Scientiﬁc) using
Prolong Gold Antifade mounting medium (Thermo Fisher Scienti-
ﬁc). Imaging for GFP ﬂuorescence was performed with a Zeiss LSM
710 confocal microscope using a PlanApoN 60/1.42-NA oil-immer-
sion objective. For imaging to detect HA staining, we used an
Olympus FluoView 1000 confocal microscope with a 60/1.42-NA
oil-immersion objective.
Quantification of EGFP Expression in Neonatal Murine HCs and
Transduction Efficiency Analysis
Whole-mount cochleas, immunostained as described earlier, were
imaged on a Zeiss LSM 710 for quantiﬁcation in ﬁve different regions
(apex, mid-apex, middle, mid-base, and base), each 250 mm long
along the axis of the organ of Corti and 800 mm apart. The laser in-
tensity was chosen based on the specimen with the strongest EGFP
signal to prevent ﬂuorescence saturation, and the same settings
were then used for each image of a set. The efﬁciency of IHC and
OHC cell transduction was evaluated by two blinded investigators us-
ing the ImageJ program (NIH Image). HCs were identiﬁed with im-
munolabeling for MYO7A. Control samples without AAV were used
to exclude autoﬂuorescence. Segments with dissection-related dam-
age were removed from the analysis.
Mouse ABR
The ABR assay was performed using a Tucker Davis Technologies
System III workstation. Mice were anesthetized by intraperitoneal in-
jection of a ketamine (100mg/kg)/xylazine (10mg/kg) cocktail. Anes-
thetized mice were then placed on a heating pad, and electrodes were
placed subcutaneously in the vertex, underneath the left or right ear,
and on the back near the tail. Tone stimuli of 4, 5.6, 8, 11.2, 16, 22, 32,
and 45.3 kHz were calibrated with a precision microphone system
(PS9200 Kit; ACO Paciﬁc), using the TDT SigCal software package.
The recorded signals were band-pass ﬁltered (300 Hz to 3 kHz) and
ampliﬁed 100,000 times. The number of acquisition trials was set to
500 averages. Maximum stimulus intensity was set to 95 dB peak
SPL with attenuation decreasing from 85 dB to 0 dB SPL at 5-dB in-
tervals. Band-pass ﬁlters (500–3,000 Hz) were applied to the traces
before analysis.
Mouse Retina
Animals were handled in accordance with the statement of the “An-
imals in Research Committee” of the Association for Research in
Vision and Ophthalmology (Rockville, MD, USA), and protocols
were approved by the local institutional committee (Service vétérin-
aire du canton de Vaud, Lausanne, Switzerland). Adult C57BL/6
mice were anesthetized with a reversible anesthetic regimen
composed of ketamine and medetomidine (ketamine, 30–60 mg/kg,
Parker Davis; medetomidine, 0.5–1 mg/kg, Graeub), and the anes-
thesia was reversed with the injection of atipamezole (0.5–1 mg/kg,MolecuGraeub). For subretinal injections, a transcleral approach was used,
and the procedure was visualized in the posterior chamber with a mi-
croscope and a coverslip covering the cornea surrounded with Visco-
tears (Novartis, Basel, Switzerland). AAV9-PHP.B-CBA-GFP vector
(1 mL) was injected into the sub-retinal space of adult mice through
a Hamilton syringe with a 34G needle (BGB Analytik).
Scanning Electron Microscopy
Organ of Corti explants were dissected at P1 and P5 in L-15 medium
and ﬁxed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer
(pH 7.2) supplemented with 2 mM CaCl2 for 1–2 hr at room temper-
ature. For older (P30) animals, after intracardial perfusion with 4%
paraformaldehyde and 1% glutaraldehyde, temporal bones were de-
calciﬁcated overnight in 10% EDTA (pH 7.2–7.4) for 3–4 days at
4C. After unpeeling cochlear bone and removing the stria vascularis
and tectorial membrane, the cochlear coils were isolated; divided into
apical, middle, and basal turns; and postﬁxed with 2.5% glutaralde-
hyde in 0.1 M cacodylate buffer (pH 7.2) supplemented with 2 mM
CaCl2 for 1–2 hr at room temperature. They were rinsed three times
in 0.1 M cacodylate buffer (pH 7.2), washed in distilled water, dehy-
drated in an ascending series of ethanol concentrations, and critical-
point dried from liquid CO2. Samples were then mounted on
aluminum stubs with carbon conductive tabs and sputter-coated
with 5 nm platinum, and then imaged in a ﬁeld-emission scanning
electron microscope (Hitachi S-4700).
Rat Cochlea
Sprague-Dawley rats (Charles River Laboratories) were injected at P1
through the RWMwith 1.2 mL vector (ss AAV9-PHP.B-CBA-GFP) at
an injection speed of 60 nL/min. The animals were allowed to recover
from the injections; after 3 days, they were euthanized, and their co-
chleas were dissected. To assess vector transduction, organ of Corti
explants were isolated, mounted on glass-bottom dishes, and cultured
as previously described.5 Transduction was assessed on the day of the
dissections (P4) or after 4 days in culture (P4+4) by visualizing the
GFP ﬂuorescence using confocal imaging.
NHP Cochlea
NHP studies were performed at Charles River Laboratories (Mon-
treal, ON, Canada) according to animal use guidelines and approved
procedures. The ﬁrst cynomolgus monkey (Macaca fascicularis) (an-
imal #1002) was a male, age 2.6 years, weighing 4 kg. The second an-
imal (animal #3501) was a female, age 3.1 years, weighing 3.2 kg.
The animals were anesthetized by intramuscular injection of a cock-
tail (ketamine, 10 mg/kg; xylazine, 0.6 mg/kg; and glycopyrrolate,
0.01 mg/kg) following overnight food deprivation, intubated, and
maintained with oxygen and isoﬂurane during surgery. During the
procedure, the following were administered to improve recovery:
warmed lactated Ringer’s solution intravenously (10 ml/kg/hr), cefa-
zolin (20 mg/kg every 20–90 min), and topical antibiotics to the sur-
gical site. The RWM was exposed using a trans-mastoid approach.
Beginning with a low microscopic magniﬁcation, the temporal mus-
cles were retracted exposing the supramastoid crest and the externallar Therapy: Methods & Clinical Development Vol. 13 June 2019 11
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with increasing magniﬁcation, mastoid air cells were burred very
closely to the cartilaginous portion of the ear canal, and the bony
portion thinned until the fossa incudis was reached, exposing the
incus. A 1- to 2-mm facial recess was then performed with awareness
of the horizontal semicircular canal, the facial nerve, and the tym-
panic membrane. The chorda tympani was retracted and/or resected,
since it was not possible to preserve it without damaging the critical
surrounding structures while allowing necessary exposure of the
round window niche. In this species, the RWM is 0.6 mm in diam-
eter. Under micromanipulator control, a 29G injection needle was
lowered through the RWM. For the ﬁrst animal, vector (10 mL) was
injected with a pump at 0.5 mL/min for 20 min, delivering 3  1011
VGs of AAV9-PHP.B-GFP into the right ear. The control left ear
was uninjected. The second animal was injected in both ears with
10 mL AAV9-PHP.B-GFP (1  1011 VGs per cochlea). Carprofen
(4 mg/kg), Rimadyl (4 mg/kg), buprenorphine (sustained release
[SR]: 0.2 mg/kg), and dexamethasone (0.75 mg/kg) were adminis-
tered at appropriate intervals during the surgical recovery period.
Animals were group housed during the observation period andmoni-
tored for reaction to treatment and body weight change.
Seven (animal #1002) or 8 (animal #3501) weeks post-surgery, the an-
imal was euthanized, and temporal bones were excised. Tissue was
ﬁxed in neutral buffered 10% formalin for 48 hr and transferred to
an EDTA solution for decalciﬁcation. Tissue was transferred to fresh
solution and periodically scanned (Faxitron X-ray) until fully decal-
ciﬁed (12 weeks) and then was embedded in parafﬁn, sectioned
(5-mm sections at 200-mm intervals to reach the mid-modiolar
cochlea), and mounted on glass slides. Slides were stained
with H&E for histopathology evaluation or left unstained for
immunohistochemistry.
Sections of cochlea were deparafﬁnized, using xylene followed by
100% and 95% ethanol washes, and then were rehydrated in water.
Sections were permeabilized with 0.5% Triton X-100 in PBS for
30 min. Sections were blocked for endogenous peroxidase using 3%
hydrogen peroxide for 10 min, washed, and then blocked using 1
Tris-buffered saline-Tween 20 (TBST)/5% normal goat serum for
1 hr at room temperature. Next, sections were incubated overnight
at 4C in primary antibody (anti-GFP antibody: GFP (D5.1) XP Rab-
bit mAb [monoclonal antibody], #2956, Cell Signaling Technology) at
a 1:200 dilution in SignalStain antibody diluent (Cell Signaling Tech-
nology), and then they were washed and incubated in SignalStain
Boost IHC Detection Reagent (horseradish peroxidase, rabbit
#8114, Cell Signaling Technology) for 30 min at room temperature.
After three washes, SignalStain diaminobenzidine (DAB) substrate
was added to slides for 1–10 min until proper staining intensity
had developed (in comparison to a negative control section such as
secondary antibody only or uninjected cochlea). Slides were
immersed in water and then counterstained with hematoxylin. Sec-
tions were washed in water, dehydrated with ethanol and xylene,
and mounted using SignalStain mounting medium. Slides were
viewed and digitized on an Olympus VS120 Virtual Slide Microscope.12 Molecular Therapy: Methods & Clinical Development Vol. 13 June 20Statistics
To compare two non-related sample groups, we used a t test for two
independent samples or a Mann-Whitney U test. For normality
testing, we used the Shapiro-Wilk test. For statistical testing, we
used GraphPad Prism software. p values < 0.05 were considered sta-
tistically signiﬁcant.
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